Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Fulgent Genetics, Inc. (FLGT) Tops Q4 EPS by $2.15, Revenues Rise 3400%; Raises Outlook
March 4, 2021 4:15 PM ESTFulgent Genetics, Inc. (NASDAQ: FLGT) reported Q4 EPS of $6.20, $2.15 better than the analyst estimate of $4.05. Revenue for the quarter came in at $295 million versus the consensus estimate of $199.44 million.
GUIDANCE:
Fulgent Genetics, Inc. sees FY2021 EPS of $12.50, versus the consensus of $11.55. Fulgent Genetics, Inc. sees FY2021 revenue of $800 million, versus the consensus of $600.24 million.
Ming Hsieh, Chairman and Chief Executive Officer, said, Our record fourth quarter results capped off a transformational year for Fulgent Genetics. While we did not envision 2020 to unfold in... More
